These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

309 related items for PubMed ID: 12955641

  • 1. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study.
    Sundar S, Jha TK, Thakur CP, Mishra M, Singh VP, Buffels R.
    Clin Infect Dis; 2003 Sep 15; 37(6):800-4. PubMed ID: 12955641
    [Abstract] [Full Text] [Related]

  • 2. Single-dose liposomal amphotericin B for visceral leishmaniasis in India.
    Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW.
    N Engl J Med; 2010 Feb 11; 362(6):504-12. PubMed ID: 20147716
    [Abstract] [Full Text] [Related]

  • 3. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations.
    Sundar S, Mehta H, Suresh AV, Singh SP, Rai M, Murray HW.
    Clin Infect Dis; 2004 Feb 01; 38(3):377-83. PubMed ID: 14727208
    [Abstract] [Full Text] [Related]

  • 4. Injectable paromomycin for Visceral leishmaniasis in India.
    Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK.
    N Engl J Med; 2007 Jun 21; 356(25):2571-81. PubMed ID: 17582067
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine.
    Sundar S, Rai M, Chakravarty J, Agarwal D, Agrawal N, Vaillant M, Olliaro P, Murray HW.
    Clin Infect Dis; 2008 Oct 15; 47(8):1000-6. PubMed ID: 18781879
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.
    Berman JD, Badaro R, Thakur CP, Wasunna KM, Behbehani K, Davidson R, Kuzoe F, Pang L, Weerasuriya K, Bryceson AD.
    Bull World Health Organ; 1998 Oct 15; 76(1):25-32. PubMed ID: 9615494
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Visceral leishmaniasis in renal transplant recipients: successful treatment with liposomal amphotericin B (AmBisome).
    Boletis JN, Pefanis A, Stathakis C, Helioti H, Kostakis A, Giamarellou H.
    Clin Infect Dis; 1999 Jun 15; 28(6):1308-9. PubMed ID: 10451172
    [Abstract] [Full Text] [Related]

  • 12. Amphotericin B--fat emulsion in treatment of visceral leishmaniasis--a cost effective substitute for liposomal amphotericin B.
    Singh GP, Saxena RK, Priyadarshy V.
    J Indian Med Assoc; 2010 Jan 15; 108(1):27-8. PubMed ID: 20839576
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence.
    Ritmeijer K, ter Horst R, Chane S, Aderie EM, Piening T, Collin SM, Davidson RN.
    Clin Infect Dis; 2011 Dec 15; 53(12):e152-8. PubMed ID: 22016502
    [Abstract] [Full Text] [Related]

  • 16. Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study.
    Laguna F, Videla S, Jiménez-Mejías ME, Sirera G, Torre-Cisneros J, Ribera E, Prados D, Clotet B, Sust M, López-Vélez R, Alvar J, Spanish HIV-Leishmania Study Group.
    J Antimicrob Chemother; 2003 Sep 15; 52(3):464-8. PubMed ID: 12888588
    [Abstract] [Full Text] [Related]

  • 17. Drug regimens for visceral leishmaniasis in Mediterranean countries.
    Gradoni L, Soteriadou K, Louzir H, Dakkak A, Toz SO, Jaffe C, Dedet JP, Campino L, Cañavate C, Dujardin JC.
    Trop Med Int Health; 2008 Oct 15; 13(10):1272-6. PubMed ID: 18764817
    [Abstract] [Full Text] [Related]

  • 18. Treatment of paediatric visceral leishmaniasis: amphotericin B or pentavalent antimony compounds?
    Kafetzis DA, Velissariou IM, Stabouli S, Mavrikou M, Delis D, Liapi G.
    Int J Antimicrob Agents; 2005 Jan 15; 25(1):26-30. PubMed ID: 15620822
    [Abstract] [Full Text] [Related]

  • 19. Safety of a pre-formulated amphotericin B lipid emulsion for the treatment of Indian Kala-azar.
    Sundar S, Chakravarty J, Agarwal D, Shah A, Agrawal N, Rai M.
    Trop Med Int Health; 2008 Sep 15; 13(9):1208-12. PubMed ID: 18664241
    [Abstract] [Full Text] [Related]

  • 20. Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions.
    Sundar S, Chakravarty J, Rai VK, Agrawal N, Singh SP, Chauhan V, Murray HW.
    Clin Infect Dis; 2007 Sep 01; 45(5):556-61. PubMed ID: 17682988
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.